Surgical management combined with leukocyte and platelet rich fibrin (L-PRF) concentrate in the medication-related osteonecrosis of the jaws treatment - case report

Authors

  • Bruno Teixeira Gonçalves Rodrigues State University of Rio de Janeiro https://orcid.org/0000-0001-7678-2588
  • Giulianna Lima Pinheiro Federal University of Rio de Janeiro
  • Roberto Prado State University of Rio de Janeiro
  • Nathália de Almeida Freire State University of Rio de Janeiro
  • Mônica Simões Israel State University of Rio de Janeiro

DOI:

https://doi.org/10.5935/2525-5711.20210005

Keywords:

Osteonecrosis, Platelet-Rich Fibrin, Alendronate, Combined Modality Therapy

Abstract

Medication-related osteonecrosis of the jaws (MRONJ) is described as an area of non- healing necrotic bone in the maxillofacial region for more than an eight-week period in patients who have received antiresorptive or antiangiogenic agents treatment, with no history of radiotherapy or metastatic disease to the jaws. A 68-year old woman medicated with oral sodium alendronate for a five-year period treating osteoporosis, presented with a painful necrotic bone exposure in the right mandible area close to the first premolar. Panoramic radiography revealed the presence of osteosclerosis and osteolysis in the area. Clinical and radiographic diagnosis was of MRONJ and antibiotic and analgesic therapy were prescribed before the surgery. Under general anesthesia, it was performed the necrotic bone curettage and use of peripheral ostectomy with a round burr in order to achieve bleeding-bone prior to the application of L-PRF membranes in the site. A two-year follow- up showed mucosa healing and at panoramic radiograph, no signs of sequestrum could be observed and no symptoms. Patient remain in clinical and radiographic follow-up with no recurrence. Therefore, the adjuvant therapy using L-PRF membranes is effective in many cases of MRONJ and should be considered as a therapeutic alternative.

Author Biographies

Bruno Teixeira Gonçalves Rodrigues, State University of Rio de Janeiro

Department of Diagnosis and Therapeutics, State University of Rio de Janeiro

Giulianna Lima Pinheiro, Federal University of Rio de Janeiro

Oral and Maxillofacial Surgery, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro

Roberto Prado, State University of Rio de Janeiro

Department of Diagnosis and Therapeutics, State University of Rio de Janeiro

Nathália de Almeida Freire, State University of Rio de Janeiro

Department of Diagnosis and Therapeutics, State University of Rio de Janeiro

Mônica Simões Israel, State University of Rio de Janeiro

Department of Diagnosis and Therapeutics, State University of Rio de Janeiro

References

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. Ameri-can Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56.

Saldanha MP, Fernandes-Moura B, Lins RX, Venturi BRM, Freire NA, Israel MS. Medi-cation-related osteonecrosis of the jaw treated by ozonized oil: a case report. J Oral Diag. 2020;5(1):e20200023.

Medeiros CKS, Santos HBP, Rolim LSA, Mororó ABG, Germano AR, Medeiros AMC. Importance of correct management of bisphosphonate-related osteonecrosis of the jaw: case report and literature review. J Oral Diag. 2018;3(1):e2018008.

Pichardo SE, Van Merkesteyn JPR. Bisphosphonate-related osteonecrosis of the jaws: spontaneous or dental origin?. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):287-92.

Cano-Durán JA, Peña-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich brin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017 Aug;9(8):e1051-9.

Dinca O, Zurac S, Staniceanu F, Bucur MB, Bodnar DC, Vladan C, et al. Clinical and his-topathological studies using fibrin-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Rom J Morphol Embryol. 2014;55(3):961-64.

Ehrenfest DM, Pinto NR, Pereda A, Jiménez P, Corso MD, Kang BS, et al. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane. Platelets. 2018 Mar;29(2):171-84.

Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 2014 Nov;52(9):854-9.

Park JH, Kim JW, Kim SJ. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?. J Oral Maxillofac Surg. 2017 Jun;75(6):1176-84.

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Sep;37(25):2270-90.

Downloads

Published

2021-01-08

How to Cite

1.
Rodrigues BTG, Pinheiro GL, Prado R, Freire N de A, Israel MS. Surgical management combined with leukocyte and platelet rich fibrin (L-PRF) concentrate in the medication-related osteonecrosis of the jaws treatment - case report. J Oral Diagn [Internet]. 2021 Jan. 8 [cited 2024 Sep. 20];6:1-5. Available from: https://jordi.com.br/revista/article/view/57

Issue

Section

Case Report